Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?

npj Primary Care Respiratory Medicine

Volumn 24, Issue , 2014, Pages

  Price, David ^a,b   Fromer, Leonard ^c   Kaplan, Alan ^d   Van Der Molen, Thys ^e   Román Rodríguez, Miguel ^f  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Research in Real Life Ltd   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Family Physician Airways Group of Canada   (Canada)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f IB Salut Balearic Health Service   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; SALMETEROL; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT; DELAYED RELEASE FORMULATION;

ASTHMA; BRONCHOCONSTRICTION; CHOLINERGIC ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PARASYMPATHETIC TONE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DELAYED RELEASE FORMULATION;

ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; HUMANS;

EID: 84904402865     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/npjpcrm.2014.23     Document Type: Review

References (89)

1. Masoli M, Fabian D, Holt S, Beasley R, The Global Initiative for Asthma. Global burden of asthma. Available at http://www.ginasthma.org/local/uploads/ files/GINABurdenReport-1.pdf (accessed 6 December 2013).
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2012. Available at http://www.ginasthma.org/local/uploads/ files/GINA-Report-2012Feb13.pdf (accessed 6 December 2013).
3. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
4. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (accessed 15 November 2013).
5. Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci 2010; 31: 335-343.
6. Canonica GW, Baena-Cagnani CE, Blaiss MS, Dahl R, Kaliner MA, Valovirta EJ, GAPP Survey Working Group. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult fi ndings. Allergy 2007; 62: 668-674. (Pubitemid 46763434)
7. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844. (Pubitemid 39346477)
8. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002; 110: 58-64. (Pubitemid 36132728)
9. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6: 13.
10. Sims EJ, Price D, Haughney J, Ryan D, Thomas M. Current control and future risk in asthma management. Allergy Asthma Immunol Res 2011; 3: 217-225.
11. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008; 102: 1681-1693.
12. O'Byrne PM, Naji N, Gauvreau GM. Severe asthma: future treatments. Clin Exp Allergy 2012; 42: 706-711.
13. Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012; 42: 38-48.
14. Iwona S, Tomasz G. Antileukotriene treatment in children with asthma - new patents. Recent Pat Inflamm Allergy Drug Discov 2008; 2: 202-211.
15. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebocontrolled trial. Lancet 2012; 380: 651-659.
16. Corren J, Lemanske RF Jr, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
17. Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007; 52: 833-851.
18. Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997; 52: 612-617. (Pubitemid 27342209)
19. Westby MJ, Benson MK, Gibson PG. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004: (3)CD003269.
20. Novelli F, Malagrinò L, Dente FL, Paggiaro P. Efficacy of anticholinergic drugs in asthma. Expert Rev Respir Med 2012; 6: 309-319.
21. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
22. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
23. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154(4 Pt 1): 876-880.
24. Fardon T, Haggart K, Lee DKC, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007; 101: 1218-1228. (Pubitemid 46679499)
25. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011; 128: 315-322.
26. Kerstjens HAM, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308-314.
27. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715-1726.
28. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207.
29. Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol 2006; 101: 971-985. (Pubitemid 44352315)
30. Molfino NA, Slutsky AS, Julià-Serdà G, Hoffstein V, Szalai JP, Chapman KR et al. Assessment of airway tone in asthma. Comparison between double lung transplant patients and healthy subjects. Am J Respir Crit Care Med 1993; 148: 1238-1243. (Pubitemid 23326020)
31. Barnes PJ. Neural mechanisms in asthma. Br Med Bull 1992; 48: 149-168.
32. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450-504.
33. Douglas NJ, Sudlow MF, Flenley DC. Effect of an inhaled atropinelike agent on normal airway function. J Appl Physiol 1979; 46: 256-262. (Pubitemid 9181117)
34. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med 1999; 107: 363-370. (Pubitemid 29465815)
35. Hashimoto A, Maeda H, Yokoyama M. Augmentation of parasympathetic nerve function in patients with extrinsic bronchial asthma-evaluation by coefficiency of variance of R-R interval with modi fied long-term ECG monitoring system. Kobe J Med Sci 1996; 42: 347-359.
36. Kesler BS, Canning BJ. Regulation of baseline cholinergic tone in guinea-pig airway smooth muscle. J Physiol 1999; 518: 843-855. (Pubitemid 29387252)
37. Jammes Y, Mei N. Assessment of the pulmonary origin of bronchoconstrictor vagal tone. J Physiol 1979; 291: 305-316. (Pubitemid 9193959)
38. Barnes PJ. Neuroeffector mechanisms: the interface between inflammation and neuronal responses. J Allergy Clin Immunol 1996; 98(5 Pt 2): S73-S81.
39. Goyal M, Jaseja H, Verma N. Increased parasympathetic tone as the underlying cause of asthma: a hypothesis. Med Hypotheses 2010; 74: 661-664.
40. Ayala LE, Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest 1989; 96: 1285-1291. (Pubitemid 20000822)
41. Barnes PJ. Modulation of neurotransmission in airways. Physiol Rev 1992; 72: 699-729.
42. Kanazawa H, Kawaguchi T, Shoji S, Fujii T, Kudoh S, Hirata K et al. Synergistic effect of nitric oxide and vasoactive intestinal peptide on bronchoprotection against histamine in anesthetized guinea pigs. Am J Respir Crit Care Med 1997; 155: 747-750. (Pubitemid 27085830)
43. Park HW, Yang MS, Park CS, Kim TB, Moon HB, Min KU et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009; 64: 778-783.
44. Lundgren R, Söderberg M, Hörstedt P, Stenling R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1: 883-889. (Pubitemid 19015298)
45. An SS, Bai TR, Bates JHT, Black JL, Brown RH, Brusasco V et al. Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J 2007; 29: 834-860. (Pubitemid 46722226)
46. Gosens R. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparative study. Abstract A269 presented at the 103rd Annual International Conference of the American Thoracic Society: San Francisco, CA, USA, 2007.
47. Gosens R, Bos IST, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005; 171: 1096-1102. (Pubitemid 40663720)
48. Milara J, Serrano A, Peiró T, Gavaldà A, Miralpeix M, Morcillo EJ et al. Aclidinium inhibits human lung fi broblast to myofibroblast transition. Thorax 2012; 67: 229-237.
49. Baker B, Peatfield AC, Richardson PS. Nervous control of mucin secretion into human bronchi. J Physiol 1985; 365: 297-305. (Pubitemid 15243752)
50. Bos IST, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007; 30: 653-661. (Pubitemid 351194824)
51. Bateman ED, Rennard S, Barnes PJ, Dicpinigaitis PV, Gosens R, Gross NJ et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009; 22: 533-542.
52. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 297-304. (Pubitemid 41566939)
53. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34: 757-769.
54. Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012; 343: 520-528.
55. Rossoni G, Manfredi B, Razzetti R, Civelli M, Berti F. Positive interaction of the novel β2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther 2007; 20: 250-257. (Pubitemid 46240951)
56. Kume H, Imbe S, Iwanaga T, Tohda Y. Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle. Abstract P4835 presented at the European Respiratory Society Annual Congress: Vienna, Austria, 2012.
57. Gaultier C, Reinberg A, Girard F. Circadian rhythms in lung resistance and dynamic lung compliance of healthy children. Effects of two bronchodilators. Respir Physiol 1977; 31: 169-182. (Pubitemid 8211434)
58. Furlan R, Guzzetti S, Crivellaro W, Dassi S, Tinelli M, Baselli G et al. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation 1990; 81: 537-547. (Pubitemid 20055962)
59. Cox ID, Hughes DTD, McDonnell KA. Ipratropium bromide in patients with nocturnal asthma. Postgrad Med J 1984; 60: 526-528. (Pubitemid 14087841)
60. Morrison JF, Pearson SB. The parasympathetic nervous system and the diurnal variation of lung mechanics in asthma. Respir Med 1991; 85: 285-289.
61. Larj MJ, Bleecker ER. Effects of β2-agonists on airway tone and bronchial responsiveness. J Allergy Clin Immunol 2002; 110(6 Suppl): S304-S312. (Pubitemid 35471720)
62. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol 2006; 31: 181-196. (Pubitemid 44804947)
63. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003; 2: 287-297. (Pubitemid 37045674)
64. Casarosa P, Pieper MP, Gantner F. Cross-talk between the human muscarinic M3 and β2 receptors: evidence for heterologous desensitization. Am J Respir Crit Care Med 2010; 181 (abs A6373).
65. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161: 1862-1868. (Pubitemid 30418121)
66. Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest 2002; 121: 1977-1987. (Pubitemid 34634423)
67. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2013: (8)CD000060.
68. Plotnick L, Ducharme F. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2000: (3) CD000060.
69. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128: 1974-1979. (Pubitemid 41507530)
70. Terzano C, Petroianni A, Ricci A, D'Antoni L, Allegra L. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci 2004; 8: 259-264. (Pubitemid 40246647)
71. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-1512. (Pubitemid 39410416)
72. Kazani S, Israel E. Long-acting β-agonists and inhaled corticosteroids: is the whole greater than the sum of its parts? J Allergy Clin Immunol 2010; 125: 357-358.
73. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118-2125. (Pubitemid 350296302)
74. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW et al. β2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181: 676-687.
75. Beeh KM, Ablinger O, Moroni-Zentgraf P, Hollaenderova Z, Pivovarova A, Engel M et al. Tiotropium in asthma: a dose-finding study in adult patients with moderate persistent asthma. Poster A1283 presented at the American Thoracic Society International Conference: Philadelphia, PA, USA, 2013.
76. Kerstjens HAM, Bleecker E, Meltzer E, Casale T, Pizzichini E, Schmidt O et al. Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: lung function and safety. Eur Respir J 2013; 42(Suppl 57): 980s (abs 4629).
77. Kerstjens HAM, Bleecker E, Meltzer E, Casale T, Pizzichini E, Schmidt O et al. Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate. Eur Respir J 2013; 42(Suppl 57): 876s (abs 4130).
78. Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf P et al. Systematic review and meta-analysis of the magnitude of the effect on the AQLQ and ACQ in asthma clinical trials. Poster P4113 presented at the European Respiratory Society Annual Congress: Barcelona, Spain, 2013.
79. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223-225. (Pubitemid 36329216)
80. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410-418. (Pubitemid 34234189)
81. Price DB, Kaplan A, Jones R, Freeman D, Burden A, Gould SE et al. Real-life prescribing and outcomes of long-acting anticholinergic therapy in adult asthma patients in UK clinical practice. Am J Respir Crit Care Med 2013; 187 (abs A2729).
82. Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981; 36: 523-529. (Pubitemid 11041556)
83. Connolly MJ. Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacol Ther 1993; 60: 389-404. (Pubitemid 24180168)
84. Partridge MR, Saunders KB. Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma. Thorax 1981; 36: 530-533. (Pubitemid 11041557)
85. Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C et al. Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax 2007; 62: 1043-1049. (Pubitemid 350206195)
86. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353: 2213-2214. (Pubitemid 29295261)
87. Bradding P, Green RH. Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol 2010; 10: 54-59.
88. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175: 783-790. (Pubitemid 46631789)
89. Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006; 174: 127-133. (Pubitemid 44015385)